Computational Chemistry And Structural Biology Approaches To Tackle Huntington's Disease

Huntington’s Disease (HD) is a fatal hereditary neurodegenerative disease caused by expansion of the CAG repeat tract at the 5’ of the huntingtin (htt) gene resulting in polyglutamine expansion of the HTT protein (polyQ-HTT) of aberrant function. HD symptoms include loss of motor coordination, cognitive and speech impairment, and psychiatric disorders. HD affects approximately 1 in 7000 people in Canada, and there are no cures or disease-modifying therapies to date.

Defining epigenetic drivers of primary and metastatic medulloblastoma

Medulloblastoma (MB) is the most common childhood brain cancer. Current treatment for these tumors is invasive involving irradiation of the entire brain and spine. Although some types of MB respond well, others have an abysmal prognosis, and the lack of less invasive therapies means that children undergoing treatment suffer from severe developmental defects and reduced quality of life.

Treating the Untreatable: Targeting Paediatric Brain Tumours with Multi-omics and Drug Discovery - Year two

Brain tumours, including ependymoma, are some of the most difficult cancers to treat. Although the past few years have seen many exciting advances in characterizing these brain tumours, there are few effective therapies available for patients, many of whom are children and young adults (and for whom long-term side effects can be extremely damaging). Until very recently, research in this area has been hampered by a complete lack of cell lines and animal models.

Discovery of Novel E3 Ligands for PROTAC Development

Protein degradation induced by PROTACs (PROteolysis TArgeting Chimeras) constitutes a novel modality of drug discovery, with advantages over the traditional approach. This approach is still at infancy and there is a lot to learn in this field. The trainees will work under academic supervisors at University of Toronto, who are experts in chemical tool development in collaboration with Structural Genomics Consortium (SGC), Toronto to expand the number of chemical tools and technologies, which will enhance the scope and understanding of PROTAC drug development.

Treating the Untreatable: Targeting Paediatric Brain Tumours with Multi-omics and Drug Discovery

Brain tumours, including ependymoma, are some of the most difficult cancers to treat. Although the past few years have seen many exciting advances in characterizing these brain tumours, there are few effective therapies available for patients, many of whom are children and young adults (and for whom long-term side effects can be extremely damaging). Until very recently, research in this area has been hampered by a complete lack of cell lines and animal models.